Corrigendum: The role of 18F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

Le résumé fourni par la source

The original version of this article has been updated.In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).'' PAGE \* Arabic \* MERGEFORMAT 3Name of all authors as they appear in the published original article (INSERT ONLY IF correcting author names or adding authors. Insert the correct version of the author list)The percentages of post-treatment changes in metabolic parameters were calculated as follows:SUVmax of pre-treatment -SUVmax of post-treatment ΔSUVmax(%) SUVmax of pretreatment = 100%  TLR of pre-treatment -TLR of post-treatment ΔTLR(%) TLR of pre-treatment = 100%  PLR of pre-treatment -PLR of post-treatment ΔPLR(%) PLR of pre-treatment = 100%  PAGE \* Arabic \* MERGEFORMAT 3In the published article, there was an error. [There is an error in the formula in the manuscript, and we hope to make changes to this error]. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.